GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2019-11-11| Trials & Approvals

Celgene, Acceleron’s novel anemia drug gets FDA green light for rare blood disorder

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

Reblozyl, became the first and only erythroid maturation agent to be FDA approved for the treatment of anemia in adults with beta thalassemia who require regular blood transfusions.

 
Introduction

Beta thalassemia is a rare, inherited blood disorder caused due to mutations in the HBB gene on chromosome 11. It is characterized by ineffective erythropoiesis, which is an abnormally low production of healthy red blood cells (RBCs) with hemoglobin, an iron-containing protein that transports oxygen in our body. The disease severity can be classified into major, intermediate or minor, based on the presence of mutations in one or two alleles. Low levels of hemoglobin cause anemia where patients experience weakness, fatigue and more serious complications due to the lack of oxygen. Although a bone marrow transplant offers a cure in many young people, the most prevalent treatment involves lifelong regimens of multiple blood transfusions which further warrants chelation therapies in some patients who experience iron overload. Last June, Bluebird Bio’s Zynteglo received conditional approval from the European Commission to treat transfusion-dependent β-thalassemia in patients 12 years and older who have no other treatment options (1).

 
FDA Approval of Reblozyl

Last Friday, the U.S. Food and Drug Administration (USFDA) approved Reblozyl (luspatercept-aamt), making it the first and only FDA-approved erythroid maturation agent (2,3). The agent reduces the RBC transfusion burden in patients by regulating their late-stage RBC maturation. This approval is on the back of statistically significant data achieved in Phase 3, BELIEVE trial (NCT02604433) that evaluated the safety and efficacy of Reblozyl in treating anemic adults with beta thalassemia who require regular RBC transfusions. In the Reblozyl arm, 21.4% of patients achieved more than 33% reduction in RBC transfusion during weeks 13–24, as compared to 4.5% in the placebo arm (risk difference [95% CI]: 17.0 [10.4, 23.6], P<0.0001), thereby reaching the primary endpoint. The study also met key secondary endpoints, by reducing transfusion burden by 33% during weeks 37-48, which was achieved in 19.6% of patients in the Reblozyl® arm versus only 3.6% in the placebo arm (risk difference [95% CI]: 16.1 [9.8, 22.4], P<0.0001).

 

Approval History

Reblozyl was co-developed by Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) as part of a global collaboration that goes way back to 2011. Last April, they announced USFDA’s acceptance of Reblozyl’s Biologics License Application (BLA) in Myelodysplastic Syndromes (MDS) and Beta-Thalassemia (4). The drug then went on to receive both Fast Track and Orphan Drug designation by the FDA.

Both companies expressed their excitement over the news. “Today’s approval is an important milestone and underscores our continued commitment to patients with hematology disorders,” said Nadim Ahmed, President, Global Hematology and Oncology for Celgene. “There are very limited options for patients living with anemia due to beta thalassemia who are dependent on long term red blood cell transfusions. We are pleased to make Reblozyl available as a new therapy for these patients to help address their anemia, a significant clinical complication of beta thalassemia.”

“We’re thrilled that Acceleron’s first approved medicine is one with the potential to help patients with beta thalassemia, who have been in need of new treatments for this lifelong disease,” said Habib Dable, President and Chief Executive Officer of Acceleron. “We are enormously grateful to the patients, families and caregivers who participated in and supported our research. Their contributions have been essential in helping to ensure that Reblozyl would emerge successfully from our longstanding collaboration with Celgene.”

According to Reuter’s, Reblozyl would be priced at $3,441 for a 25-milligram vial and is expected to enter the market within a week of its approval (5). The FDA is currently reviewing the drug for the treatment of MDS based on the results from the Phase 3 MEDALIST trial.

 

References
  1. https://www.nature.com/articles/d41587-019-00026-3
  2. https://ir.celgene.com/press-releases/press-release-details/2019/FDA-Approves-REBLOZYL-luspatercept-aamt-for-the-Treatment-of-Anemia-in-Adults-With-Beta-Thalassemia-Who-Require-Regular-Red-Blood-Cell-Transfusions/default.aspx
  3. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-patients-beta-thalassemia
  4. https://www.drugs.com/history/reblozyl.html
  5. https://www.reuters.com/article/us-celgene-fda/u-s-fda-approves-celgenes-rare-blood-disorder-drug-idUSKBN1XI25M

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
FDA Grants First-Ever Approval for MSC Therapy to Australian Company Mesoblast After Attempting for 4 Years
2024-12-20
FDA Approves Kebilidi: First Brain-Delivered Gene Therapy for Rare AADC Disease
2024-11-15
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top